IL292834A - An application for animals that includes voluntary and business services and a consultation forum of a veterinarian and an online trainer. - Google Patents
An application for animals that includes voluntary and business services and a consultation forum of a veterinarian and an online trainer.Info
- Publication number
- IL292834A IL292834A IL292834A IL29283422A IL292834A IL 292834 A IL292834 A IL 292834A IL 292834 A IL292834 A IL 292834A IL 29283422 A IL29283422 A IL 29283422A IL 292834 A IL292834 A IL 292834A
- Authority
- IL
- Israel
- Prior art keywords
- polypeptide
- binding compound
- recombinant
- polypeptides
- adenovirus
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title 1
- 230000002747 voluntary effect Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 31
- 102000004196 processed proteins & peptides Human genes 0.000 claims 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims 31
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 23
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 20
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 16
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 16
- 241000701161 unidentified adenovirus Species 0.000 claims 12
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims 6
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 6
- 210000000234 capsid Anatomy 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 3
- 102000048362 human PDCD1 Human genes 0.000 claims 3
- 239000012830 cancer therapeutic Substances 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 108010082808 4-1BB Ligand Proteins 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 108010014173 Factor X Proteins 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 102000004473 OX40 Ligand Human genes 0.000 claims 1
- 108010042215 OX40 Ligand Proteins 0.000 claims 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 1
- 229930003448 Vitamin K Natural products 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 102000048776 human CD274 Human genes 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 235000019168 vitamin K Nutrition 0.000 claims 1
- 239000011712 vitamin K Substances 0.000 claims 1
- 150000003721 vitamin K derivatives Chemical class 0.000 claims 1
- 229940046010 vitamin k Drugs 0.000 claims 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (20)
1. A multivalent programmed death ligand 1 (PD-L1) binding compound comprising, a recombinant Adenovirus (Ad) comprising capsid hexon polypeptides of an Adenovirus strain Ad6 and at least one capsid hexon hypervariable region (HVR) polypeptide from Adenovirus strain Ad57, wherein the recombinant Ad comprises at least one programmed cell death protein 1 (PD-1) polypeptide, and wherein the recombinant Ad comprises nucleic acids which encode one or more therapeutic polypeptides.
2. The PD-L1 binding compound of Claim 1, wherein the capsid hexon polypeptides of the Adenovirus strain Ad6 comprise HVR polypeptides 1-from Adenovirus strain Ad57.
3. The PD-L1 binding compound of Claim 1, wherein the capsid hexon polypeptides of the Adenovirus strain Ad6 comprise HVR polypeptides 2-from Adenovirus strain Ad57.
4. The PD-L1 binding compound of Claim 1, wherein the recombinant Ad is a conditionally-replicating Adenovirus (CRAd) which has been modified in an E1A gene encoding an E1A polypeptide, wherein the CRAd exhibits amino acid substitutions in the E1A polypeptide relative to wild-type E1A polypeptide of an Ad strain.
5. The PD-L1 binding compound of Claim 4, wherein the recombinant Ad is a conditionally-replicating Adenovirus (CRAd) wherein the N-terminal portion of the E1A polypeptide comprises an amino acid sequence set forth in SEQ ID NO:32, SEQ ID NO:33 or SEQ ID NO:34. 292788/
6. The PD-L1 binding compound of Claim 1, wherein the PD-1 polypeptide is in the form of a fusion protein with a heterologous polypeptide.
7. The PD-L1 binding compound of Claim 6, wherein the PD-1 polypeptide is fused to a heterologous polypeptide which is a Vitamin K-dependent gamma-carboxyglutamic domain of a factor X single-chain antibody polypeptide (a GLA domain of an FX polypeptide).
8. The PD-L1 binding compound of Claim 1, wherein the PD-1 polypeptide is a human PD-1 or a murine PD-1.
9. The PD-L1 binding compound of Claim 1, wherein the PD-1 polypeptide is modified for higher affinity interactions with PD-L1.
10. The PD-L1 binding compound of Claim 1, wherein the PD-1 polypeptide is a fragment of a human PD-1 polypeptide, wherein the fragment of the human PD-1 polypeptide comprises one or more amino acid changes relative to a wild type PD-1, which changes cause an increased affinity for human PD-L1.
11. The PD-L1 binding compound of Claim 1, wherein the recombinant Ad comprises an expression cassette comprising a promoter operably linked to nucleic acids encoding a PD-1 polypeptide which allows for expression of the PD-1 polypeptide in eukaryotic cells.
12. The PD-L1 binding compound of Claim 1, wherein the recombinant Ad comprises nucleic acids which encode one or more therapeutic polypeptides.
13. The PD-L1 binding compound of Claim 12, wherein the recombinant Ad comprises nucleic acids which encode an antibody.
14. The PD-L1 binding compound of Claim 1, wherein the recombinant Ad comprises an expression cassette comprising a promoter operably linked to 292788/ nucleic acids encoding a therapeutic polypeptide which allows for expression of therapeutic polypeptides in eukaryotic cells.
15. The PD-L1 binding compound of Claim 14, wherein the therapeutic polypeptides are selected from a 4-1BB ligand polypeptide, a OX40 ligand polypeptide, a CD40 ligand polypeptide, and a granulocyte-macrophage colony-stimulating factor polypeptide.
16. A pharmaceutical composition comprising the PD-L1 binding compound of Claim 1 and a pharmaceutically acceptable carrier.
17. The multivalent PD-L1 binding compound of Claim 1 for use in treating cancer.
18. The compound for use according to Claim 17, for administration together with one or more cancer therapeutics.
19. The compound for use according to Claim 18, wherein the cancer therapeutic is an immunotherapy which targets PD-1/PD-L1 pathways.
20. A multivalent programmed death ligand 1 (PD-L1) binding compound comprising a recombinant Adenovirus (Ad) comprising capsid hexon polypeptides of an Adenovirus strain Ad6 and at least one capsid hexon hypervariable region (HVR) polypeptide from Adenovirus strain Ad57, wherein the recombinant Ad comprises a plurality of amino acid chains displayed on the surface of the recombinant Ad, wherein each amino acid chain comprises at least one programmed cell death protein 1 (PD-1) polypeptide, wherein the recombinant Ad comprises at least one programmed cell death protein 1 (PD-1) polypeptide, and wherein cancer cells of the cancer are positive for PD-L1 expression, 292788/ for use in treating cancer. For the Applicant Naschitz Brandes Amir & Co. P-16879-IL1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL292834A IL292834A (en) | 2022-05-08 | 2022-05-08 | An application for animals that includes voluntary and business services and a consultation forum of a veterinarian and an online trainer. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL292834A IL292834A (en) | 2022-05-08 | 2022-05-08 | An application for animals that includes voluntary and business services and a consultation forum of a veterinarian and an online trainer. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL292834A true IL292834A (en) | 2023-12-01 |
Family
ID=89068988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL292834A IL292834A (en) | 2022-05-08 | 2022-05-08 | An application for animals that includes voluntary and business services and a consultation forum of a veterinarian and an online trainer. |
Country Status (1)
| Country | Link |
|---|---|
| IL (1) | IL292834A (en) |
-
2022
- 2022-05-08 IL IL292834A patent/IL292834A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Smith et al. | In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus–adenovirus receptor | |
| Schmidt | Fusion protein technologies for biopharmaceuticals: applications and challenges | |
| JP2019502379A (en) | Group B adenovirus encoding anti-TCR complex antibody or fragment | |
| US20140369979A1 (en) | Vector simultaneously expressing dodecameric trail and hsv-tk suicide genes, and anticancer stem cell therapeutic agent using same | |
| KR20120049185A (en) | Oncolytic adenoviruses for treating cancer | |
| JP2020511954A (en) | Multi-site SSI cells for difficult-to-express proteins | |
| JPWO2015098989A1 (en) | A novel anti-transferrin receptor antibody that crosses the blood-brain barrier | |
| WO2003062400A2 (en) | Fiber shaft modifications for efficient targeting | |
| US20210017501A1 (en) | Modified oncolytic adenoviruses | |
| Brücher et al. | iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy | |
| Berger et al. | Fusion protein technologies for biopharmaceuticals: Applications and challenges: Editor Stefan R Schmidt | |
| JP2005515784A (en) | Adenoviral vector for modulating cellular activity associated with POD | |
| KR20210094531A (en) | Split interleukin mimetics and uses thereof | |
| JPWO2020223537A5 (en) | ||
| IL292788B1 (en) | Multivalent pd-l1 binding compounds for treating cancer | |
| IL292834A (en) | An application for animals that includes voluntary and business services and a consultation forum of a veterinarian and an online trainer. | |
| US20210347842A1 (en) | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy | |
| JP2006502726A (en) | Improved immunotherapy | |
| Martel-Renoir et al. | Coelectrotransfer to skeletal muscle of three plasmids coding for antiangiogenic factors and regulatory factors of the tetracycline-inducible system: tightly regulated expression, inhibition of transplanted tumor growth, and antimetastatic effect | |
| Zhan et al. | Fusion of HSA influences TNF-α neutralizing activity of shTNFRs | |
| Palmer et al. | Gene-and immunotherapy for hepatocellular carcinoma | |
| AU2003206663B9 (en) | Microorganism for genetic therapeutic treatment of proliferative diseases | |
| US20050003548A1 (en) | Targeted adenoviral vector displaying immunoglobulin-binding domain and uses thereof | |
| CA2410981A1 (en) | Adenovirus particles with mutagenized fiber proteins | |
| JPH04229188A (en) | In-vitro processing of fusion protein |